Wikipedia

User:Wxu68/Into Neuroscience-Dr. Potter/Wen Xu

< User:Wxu68 | Into Neuroscience-Dr. Potter
(Redirected from User:Wxu68/Into Neuroscience-Dr. Potter)

This page is edited by Wen Xu

Estrogen and Neurodegenerative Diseases

One thing links estrogen and neurodegenerative diseases together is known as the Estrogen Replacement Therapy. It is reported that females and males suffer different risk of different types of diseases which cannot set aside neurodegenerative diseases.[1] Discovered the sexual difference in people suffering such diseases, scientists found the thing that really mattered was estrogen, the well known female hormone. Estrogen was found to have many effective aspects of neurodegenerative diseases but can not be a treatment for many reasons. The most important side effect is its ability to higher the chances of getting other diseases such as breast cancer and coronary heart disease. Since estrogen is a large family of molecules that can result in a different function to human, systems for screening such molecules were developed. Also, scientists discovered ways to make their own estrogen-like compounds that can perfectly avoid most side effects used synthetic biochemistry to discover new molecules.

Estrogen

edit
 
17-alpha- vs 17-beta-estradiol

Introduction

edit

Estrogen is a kind of lipid hormones in human which has comparative activity and can regulate many physiological processes.[2] Estrogen is known as the female sex hormone and is largely related to menstrual and estrous. Its biological function is mediated by two receptors: Estrogen Receptor alpha(ERα ) and Estrogen Receptor beta(ERβ ). The two receptors are tissue specific and have different influences on their downstream genes.[3] Decrease of estrogen could lead to many diseases like osteoporosis. Estrogen could work on many genes to regulate physiological activities and low estrogen concentration might lead to a series of cognitive diseases. Estrogen can be divided into four classes:

Animal Estrogens

In this family, three main members in woman are estrone (E1), estradiol (E2), and estriol (E3). Estradiol is the most dominant and studied one among them.

Plant Estrogens (Phytoestrogens)

Produced by plants. These estrogens can cause estrogenic effects by people consuming them. They are structurally similar to estradiol.

Fungi Estrogens (mycoestrogens)

Produced by fungi. It can also affect the human estrogen level by consuming them.

Synthetic Estrogens (xenoestrogens)

A large number of compounds that are synthesized or naturally existed. These estrogens imitate estrogen structural and can be designed to satisfy the need of new drugs. But they may also cause serious problems so they need to be used carefully.

Medical Application

edit

The application of estrogen on medicine can be divided into a number of aspects. The most well know ones are breast cancer and coronary heart disease. Estrogen also plays very important role in animal metabolism balance. These main diseases caused by Estrogen have a relationship with neurodegenerative diseases since human hormone balance has a wide range of influence on all sides.

Breast Cancer

edit

Breast cancer is a type of cancer originating from breast tissue, most commonly from the inner lining of milk ducts or the lobules that supply the ducts with milk.[4] Cancers originating from ducts are known as ductal carcinomas, while those originating from lobules are known as lobular carcinomas. Breast cancer occurs in humans and other mammals. While the overwhelming majority of human cases occurs in women, male breast cancer can also occur.[5]

Estrogen and breast cancer

edit

For breast cancer patients, endocrine therapy with selective estrogen receptor modulators (SERMs) to suppress the growth of estradiol sensitive breast tumors.[6] But it has also been hypothesized that higher levels of endogenous hormones increase the risk of breast cancer. The most prevalent idea is estrogen's carcinogenic effect on breast cancer. The involvement of estrogen-receptor-mediated signaling leads to the production of reactive metabolites that may exert genotoxic effects.[7]

Coronary artery disease

edit

Coronary artery disease (CAD) is a kind of disease that has plaque building up along the inner walls of the coronary arteries and narrows the arteries then reduces blood flow to the heart to affect oxygen supplement to heart muscles.[8] The main causes of coronary heart disease mainly include: age, sex, family history, smoking, high levels of certain fats and cholesterol in the blood, high blood pressure, high levels of sugar in the blood due to insulin resistance or diabetes and blood vessel inflammation.[8]

Estrogen and coronary heart diseases

edit

The Framingham study found out that cardiovascular risk is accentuated for women in particular and many following studies have documented worsened cardiac outcomes for women. Since estrogen has strong regulation of common intracellular signaling pathways in the maintenance of cardiomyocyte function and underlying aspects of female cardiovascular pathophysiology, estrogen can have great influence on coronary heart diseases.[9]

Neurodegenerative Diseases

edit

Introduction

edit
Main article: Neurodegeneration

Neurodegenerative diseases are diseases caused along the process of neurodegeneration. Neurodegeneration includes structural and functional loss of neurons or even the death of the neurons. The causes of such diseases can be various but can be concluded into four aspects: genetic mutation, protein misfolding, intracellular mechanisms and programmed cell death.

Main Classes of Neurodegenerative Diseases

edit

Alzheimer's Disease

edit

Alzheimer's disease(AD) is the most common form of dementia. There are many common symptoms of this disease although it is developed differently in every individual. In the early stages, patients often suffer difficulty in remembering recent events. As the disease advances, symptoms can include confusion, irritability, aggression, mood swings, trouble with language, and long-term memory loss. Gradually, bodily functions are lost, ultimately leading to death.

Parkinson's Disease

edit

Parkinson's disease(PD) is a neurodegenerative disorder of the central nervous system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain while the cause of this cell death is unknown.

 
Huntington

Huntington's Disease

edit

Huntington's disease (HD) is a neurodegenerative genetic disorder that affects muscle coordination and leads to cognitive decline and psychiatric problems. HD causes astrogliosis[10] and loss of medium spiny neurons.[11][12]

Amyotrophic lateral sclerosis

edit

Amyotrophic lateral sclerosis (ALS) is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and difficulty breathing (dyspnea).

Efforts Made on Therapy

edit

Different neurodegenerative diseases have different causes and are not well studied until now. There is no clear cure for such diseases but some efforts have been made to research deeper into them. The 10th Global College of Neuroproetction and Neuroregeneration Annual Conference together with the International Association of Neurorestoratology VI was held to discuss on neurorestoration, neuroprotection and neuroregeneration in various clinical neurodegenerative diseases like Alzheimer's, Parkinson's, Huntington's disease, stroke and brain or spinal cord injuries.[13] The main aim was to enhance health care by the use of stem cells, nanodrug delivery of drugs and stem cells, use of multimodal drugs as well as a combination of different approaches. They concluded that the future of neuroprotection could be achieved by the use of stem cells and nanodrug delivery in chronic neurological disorders.[13]

Estrogen and neurodegenerative diseases

edit

Although estrogen is best known for its effects on the maturation and differentiation of the primary and secondary sex organs, increasing evidence suggests that its influence extends beyond this system, and its activity in the CNS may initiate, or influence our susceptibility to neurodegenerative decline. Estrogen has been proposed to act as a neuroprotectant at several levels, and it is probable that deprivation of estrogen as a result of menopause exposes the aging or diseased brain to several insults. In addition, estrogen deprivation is likely to initiate or enhance degenerative changes caused by oxidative stress, and to reduce the brain's ability to maintain synaptic connectivity and cholinergic integrity leading to the cognitive decline seen in aged and disease-afflicted individuals.[14] There is sufficient evidence that estradiol is a powerful neuroprotectant which might have use against not only AD, but also stroke and Parkinson’s disease, both in women and men, and the development of better estrogen derivatives should be considered a priority.[14]

Estrogen and Alzheimer's disease

edit
 
Different secretase cleave different sites of APP thus cause different effects.

Neurofibrillary tangles formed by amyloid-β (Aβ) deposition and amyloid plaques formed by tau protein phosphorylation are dominant physiological features of Alzheimer's disease. Amyloid precursor protein (APP) proteolysis is fundamental for production of Aβ peptides implicated in AD pathology.[15] By using a cell line that contains high levels of estrogen receptors, scientists found that treatment with physiological concentrations of 17 beta-estradiol is associated with accumulation in the conditioned medium of an amino-terminal cleavage product of APP (soluble APP or protease nexin-2), indicative of non-amyloidogenic processing.[16]

Estrogen and Parkinson's disease

edit

Estrogen deprivation leads to the death of dopamine cells in the brain that could have implications for post-menopausal women, but the majority of clinical reports support an antidopaminergic effect of estrogens on Parkinsonian symptoms.[17] So recommendations on the use of postmenopausal hormonal replacement therapy in women with Parkinson's disease or those genetically at risk.[18] But another group of scientists found a positive association between estrogen use and lower symptom severity in women with early PD not yet taking L-dopa.[19]

Estrogen and Huntington's disease

edit

Huntington's disease (HD) is a polyglutamine disorder based on an expanded CAG triplet repeat[20] leading to cerebral and striatal neurodegeneration. [21]Potential sex differences concerning the age of onset and the course of the disease are poorly defined, as difficulties of matching female and male HD patients regarding their CAG repeat lengths limit comparability. [22]

Estrogen and Amyotrophic lateral sclerosis

edit

ALS occurs more commonly in men than in women, and women get the disease later in life compared to men.[23] This suggest the possible protective role of estrogen in ALS. By conducting treatment of 17β-estradiol to ovariectomy treated mice, scientists found significantly delay of disease progression.[24]

Estrogen Replacement Therapy

edit

Introduction

edit

Estrogen Replacement Therapy is a kind of hormone replacement therapy. Its goal is to mitigate discomfort caused by diminished circulating estrogen in menopause. The 2002 Women's Health Initiative of the National Institutes of Health found disparate results for all cause mortality with hormone replacement, finding it to be lower when HRT was begun earlier, between age 50-59, but higher when begun after age 60. In older patients, there was an increased incidence of breast cancer, heart attacks and stroke, although a reduced incidence of colorectal cancer and bone fracture.[25] Some of the WHI findings were again found in a larger national study done in the UK, known as The Million Women Study. As a result of these findings, the number of women taking hormone treatment dropped precipitously.[26] The Women's Health Initiative recommended that women with non-surgical menopause take the lowest feasible dose of HRT for the shortest possible time to minimize associated risks.[25]

Main Pathways

edit

The role of estrogens is mostly mediated by two nuclear receptors (ER alpha and ER beta) and a membrane-associated G-protein (GPR30 or GPER), and it is not limited to reproduction, but it extends to the skeletal, cardiovascular and central nervous systems. Various pathologies such as cancer, inflammatory, neurodegenerative and metabolic diseases are often associated with dysfunctions of the estrogen system. Therapeutic interventions by agents that affect the estrogen signaling pathway might be useful in the treatment of many dissimilar diseases.[27]

Application

edit

The receptors of estrogen are specially distributed in different tissues, which have different influence on their downstream genes. The activation of the two different estrogen receptors have different effects on human. ERα and ERβ also mediate Selective estrogen-receptor modulators’ (SERMs’) function,[28] but the selective ERα agitator can always cause some side effects such as breast cancer or endometrial hyperplasia, while the selective ERβ agitator may play an active effect on such diseases. So, the selective ERβ agitator has more clinical value for neurodegenerative diseases. In post-menopausal women, high levels of testosterone and estrogen higher the risk 2-3 times than lower level situation. Women that are not taking hormone replacement therapy (HRT) have lesser risk of breast cancer because of the insulin level increase.[29]

Nonsteroidal estrogens

edit

Introduction

edit

Nonsteroidal estrogens include xenoestrogens, phytoestrogens and mycoestrogens. They are very useful in neurodegenerative diseases' therapy when considering about the side effects caused by estradiol. As the development of chemical synthesis, it becomes more and more possible for people to construct new molecules as they like. The fact that an extremely large number of naturally occurring compounds, and an unlimited number of synthetic compounds, have an estrogen-like activity has been exploited by the drug companies to produce patented proprietary drugs, especially the contraceptives.[30] Phytoestrogens are plant derived estrogens and have similar structures with 17beta-estradiol thus may cause estrogenic or anti-estrogenic effects.[31] Mycoestrogens are produced by fungi and are commonly found in stored grain.

Application

edit

Nonsteroidal estrogens prevalently exist in our environment and have both positive and negative effects on our daily life. But as a possible way to get access to neurodegenerative disease treatment, scientists have developed multiple ways to screen these estrogens and select the ones that have less side effects. Bipartite recombinant yeast system and dual fluorescence report system are designed to screen these potential chemicals.[32][33]

References

edit
  1. ^ Fratiglioni, L (December 1991). "Prevalence of Alzheimer's disease and other dementias in an elderly urban population". Neurology. 41 (12): 1886–1892. doi:10.1212/WNL.41.12.1886. PMID 1745343. S2CID 43648760. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  2. ^ Leung, Kin-Chuen (October 2004). "Estrogen Regulation of Growth Hormone Action". Endocrine Reviews. 25 (5): 693–721. doi:10.1210/er.2003-0035. PMID 15466938. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  3. ^ Pettersson, Katarina (March 2001). "Role of Estrogen Receptor Beta in Estrogen Action". Annual Review of Physiology. 63: 165–192. doi:10.1146/annurev.physiol.63.1.165. PMID 11181953. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  4. ^ Sariego J (2010). "Breast cancer in the young patient". The American Surgeon. 76 (12): 1397–1401. doi:10.1177/000313481007601226. PMID 21265355. S2CID 22161840.
  5. ^ US NIH: Male Breast Cancer
  6. ^ Buwalda, Bauke (October 2013). "Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?". Cancer, Chemotherapy and Cognition. 93 (17): 581–588. doi:10.1016/j.lfs.2012.12.012. PMID 23353876. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  7. ^ Cerne, Jasmina-Ziva (January 2013). "Breast cancer: estrogens as carcinogens". Zdravniski Vestnik-Slovenian Medical Journal. 82 (1): 41–46. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  8. ^ a b "Coronary artery disease". wikipedia.
  9. ^ Reichelt, Melissa E. (September 2013). "Sex, sex steroids, and diabetic cardiomyopathy: making the case for an experimental focus". American Journal of Physiology-Heart and Circulatory Physiology. 305 (6): H779–H792. doi:10.1152/ajpheart.00141.2013. PMID 23792676. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  10. ^ Lobsiger CS, Cleveland DW (November 2007). "Glial cells as intrinsic components of non-cell autonomous neurodegenerative disease". Nat. Neurosci. 10 (11): 1355–60. doi:10.1038/nn1988. PMC 3110080. PMID 17965655.{{cite journal}}: CS1 maint: date and year (link)
  11. ^ Purves D, Augustine GA, Fitzpatrick D, Hall W, LaMantia A-S, McNamara JO, Williams SM (2001). "Modulation of Movement by the Basal Ganglia - Circuits within the Basal Ganglia System". In Dale Purves (ed.). Neuroscience (2nd ed.). Sunderland, MA: Sinauer Associates. ISBN 0-87893-742-0.{{cite book}}: CS1 maint: multiple names: authors list (link)
  12. ^ Estrada Sánchez AM, Mejía-Toiber J, Massieu L (April 2008). "Excitotoxic neuronal death and the pathogenesis of Huntington's disease". Arch. Med. Res. 39 (3): 265–76. doi:10.1016/j.arcmed.2007.11.011. PMID 18279698.{{cite journal}}: CS1 maint: date and year (link) CS1 maint: multiple names: authors list (link)
  13. ^ a b Sharma, Hari S. (October 2013). "Novel therapeutic strategies using nanodrug delivery, stem cells and combination therapy for CNS trauma and neurodegenerative disorders". Expert Review of Neurotherapeutics. 13 (10): 1085–1088. doi:10.1586/14737175.2013.836297. PMID 24089700. S2CID 24356630. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  14. ^ a b Gandy, S. (July 2003). "Estrogen and neurodegeneration". Neurochemistry Research. 28 (7): 1003–8. doi:10.1023/A:1023246921127. PMID 12737524. S2CID 12116802.{{cite journal}}: CS1 maint: date and year (link)
  15. ^ Zhang, She-Qing (August 2013). "Octyl Gallate Markedly Promotes Anti-amyloidogenic Processing of APP through Estrogen Receptor-Mediated ADAM10 Activation". PLOS ONE. 8 (8). {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  16. ^ JAFFE, AB (1994). "ESTROGEN REGULATES METABOLISM OF ALZHEIMER AMYLOID-BETA PRECURSOR PROTEIN". Journal of Biological Chemistry. 269 (18): 13065–13068. doi:10.1016/S0021-9258(17)36796-0. PMID 8175728. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  17. ^ Session, D.R. (April 1994). "Estrogens and Parkinson's disease". Medical Hypotheses. 42 (4): 280–282. doi:10.1016/0306-9877(94)90133-3. PMID 8072437. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  18. ^ Kompoliti, K (May 2003). "Estrogen and Parkinson's disease". Frontier in Bioscience. 8: 391–400.{{cite journal}}: CS1 maint: date and year (link)
  19. ^ Pullman, R. Saunders (April 1999). "The effect of estrogen replacement on early Parkinson's disease". Neurology. 52 (7): 1417–1421. doi:10.1212/WNL.52.7.1417. PMID 10227628. S2CID 24749803. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  20. ^ The Huntington's Disease Collaborative Research Group (1993). "The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes". Cell. 72 (6): 971–983. doi:10.1016/0092-8674(93)90585-E. hdl:2027.42/30901. PMID 8458085. S2CID 802885.
  21. ^ Vonsattel, J.P. (198). "Huntington disease". Neuropathol. Exp. Neurol. 57 (5): 369–384. doi:10.1097/00005072-199805000-00001. PMID 9596408. S2CID 35547780. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  22. ^ Bode, Felix J. (May 2008). "Sex differences in a transgenic rat model of Huntington's disease: decreased 17β-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males". Human Molecular Genetics. 17 (17): 2595–2609. doi:10.1093/hmg/ddn159. PMID 18502785. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  23. ^ Rudnicki, SA (October 1999). "https://en.wikipedia.org/wiki/Estrogen_and_neurodegenerative_diseases#Estrogen_and_Amyotrophic_lateral_sclerosis". Journal of Neurological Sciences. 169 (1–2): 126–7. doi:10.1016/S0022-510X(99)00234-8. PMID 10540020. S2CID 29442303. {{cite journal}}: External link in |title= (help)CS1 maint: date and year (link)
  24. ^ Groenerveld, G.J. (September 2004). "Ovariectomy and 17β-estradiol modulate disease progression of a mouse model of ALS". Brain Research. 1021 (1): 128–131. doi:10.1016/j.brainres.2004.06.024. PMID 15328040. S2CID 38207502. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  25. ^ a b Writing Group for the Women's Health Initiative Investigators (2002). "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial". JAMA. 288 (3): 321–333. doi:10.1001/jama.288.3.321. PMID 12117397. S2CID 20149703.
  26. ^ Chlebowski, Rowan T.; Kuller, Lewis H.; Prentice, Ross L.; Stefanick, Marcia L.; Manson, Joann E.; Gass, Margery; Aragaki, Aaron K.; Ockene, Judith K.; Lane, Dorothy S.; Sarto, Gloria E.; Rajkovic, Aleksandar; Schenken, Robert; Hendrix, Susan L.; Ravdin, Peter M.; Rohan, Thomas E.; Yasmeen, Shagufta; Anderson, Garnet; WHI Investigators (2009). "Breast cancer after use of estrogen plus progestin in postmenopausal women". NEJM. 360 (6): 573–87. doi:10.1056/NEJMoa0807684. PMC 3963492. PMID 19196674.
  27. ^ Paterni, Ilaria (October 2013). "Estrogen receptor ligands: a patent review update". Expert Opinion on Therapeutic Patents. 23 (10): 1247–1271. doi:10.1517/13543776.2013.805206. PMID 23713677. S2CID 6259593. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  28. ^ Riggs, B. Lawrence (February 2003). "Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice". New England Journal of Medicine. 348 (7): 618–629. doi:10.1056/NEJMra022219. PMID 12584371. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  29. ^ Tariq, Rabia (August 2013). "Risk factors and prevalence of breast cancer- a review". Journal of Pakistan Medical Association. 63 (8): 1075–1078. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  30. ^ "Natural Estrogens".
  31. ^ "Phytoestrogens". wikipedia.
  32. ^ Liang, K (January 2009). "A bipartite recombinant yeast system for the identification of subtype-selective estrogen receptor ligands". Molecular Biotechnology. 41 (1): 53–62. doi:10.1007/s12033-008-9097-9. PMID 18751932. S2CID 36754149. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)
  33. ^ Zhang, X (July 2013). "Design, synthesis and biological evaluation of novel estrogen-derived steroid metal complexes". Bioorganic& Medical Chemistry Letters. 23 (13): 3793–7. doi:10.1016/j.bmcl.2013.04.088. PMID 23726343. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date and year (link)


Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Wxu68/Into_Neuroscience-Dr._Potter/Wen_Xu&oldid=1169313711"